Switch to Oral Antibiotics in Gram-negative Bacteremia

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

176 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-10-13

Study Completion Date

2023-07-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Eligible subjects will be those age 18 years or more with mono-microbial blood stream infection caused by E. coli, Klebsiella species, Enterobacter species, Serratia species, Citrobacter species, or Proteus species, who have achieved adequate source control, are afebrile and hemodynamically stable for 48 hours or more and have received microbiologically active intravenous therapy for 3-5 days. The bloodstream isolate must be susceptible to amoxicillin, amoxicillin-clavulanate, fluoroquinolones, oral cephalosporins and/or trimethoprim-sulfamethoxazole and the subject must be able to take oral medication directly or through a feeding tube. Exclusions criteria include allergy to all in-vitro active antimicrobials which are available in oral formulations, pregnancy, infective endocarditis, central nervous system infection, terminal illness with expected survival less than 14 days, absolute neutrophil count less than 1,000/ml and hematopoietic or solid organ transplantation within the preceding 90 days. Randomization will be stratified by urinary versus non-urinary source of bacteremia. The primary outcome is treatment failure at 90-days with 10% margin for non-inferiority in the 95% confidence interval around the difference in outcome between the two study groups.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Duration of Antibiotics for the Treatment of Gram-negative Bacilli Bacteremia

NCT01737320

Gram Negative Bacteremia

COMPLETED NA

Early Oral Step-down Antibiotic Therapy for Uncomplicated Gram-negative Bacteraemia

NCT05199324

Gram-negative Bacteraemia

RECRUITING PHASE4

Antibiotic Treatment Duration (7 vs 14 Days) Comparison in Blood Stream Infection Causes by Enterobacteriaceae

NCT02400268

Enterobacteriaceae Infections Bloodstream Infection

COMPLETED PHASE3

Clinical Impact of Fluoroquinolone Resistance in Bacteremia Caused by Gram-Negative Bacilli of Urinary Tract Origin

NCT00414362

Urinary Tract Infection Fluoroquinolone Bacteremia

COMPLETED

Pharmacodynamics Modeling to Optimize Dosage Regimens of Sulbactam in Patients With Acinetobacter Infections

NCT02688322

Acinetobacter Infections

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Oral antimicrobial therapy mitigates vascular line associated complications such as infection, thrombosis and pain, facilitating early mobilization and discharge and reducing healthcare costs. Efficacy and safety of step-down to oral antimicrobial therapy in patients with Enterobacteriaceae bacteremia has never been confirmed in a randomized clinical trial. The aim of this clinical trial is to evaluate the safety and efficacy of oral step down strategy in patients with Gram-negative blood stream infections.

Eligible subjects will be those age 18 years or more with mono-microbial blood stream infection caused by E. coli, Klebsiella species, Enterobacter species, Serratia species, Citrobacter species, or Proteus species, who have achieved adequate source control, are afebrile and hemodynamically stable for 48 hours or more and have received microbiologically active intravenous therapy for 3-5 days. The bloodstream isolate must be susceptible to amoxicillin, amoxicillin-clavulanate, fluoroquinolones, oral cephalosporins and/or trimethoprim-sulfamethoxazole and the subject must be able to take oral medication directly or through a feeding tube. Exclusions criteria include allergy to all in-vitro active antimicrobials which are available in oral formulations, pregnancy, infective endocarditis, central nervous system infection, terminal illness with expected survival less than 14 days, absolute neutrophil count less than 1.0x109/L and hematopoietic or solid organ transplantation within the preceding 90 days.

The primary endpoint is treatment failure at 90-days, defined as a composite of the death from any cause, need for additional antimicrobial therapy with one or more microbiologically active agents before complete resolution of signs and symptoms of infection, microbiological relapse (same species from any clinical site) and infection-related re-admission.

Eligible subjects will be randomized using permuted blocks of variable sizes to full intravenous antimicrobial therapy course (IV Group) or intravenous followed by step-down to oral therapy (PO Group). Randomization will be stratified by urinary versus non-urinary source of bacteremia. The primary analysis will include all patients who were randomized and received at least one dose of the assigned treatment. The difference in primary outcome rate between the intervention and control groups will be presented alongside a 95% confidence interval (CI), adjusted by source of bacteremia. If the upper limit of the 95% CI for the difference in overall response is below 10%, non-inferiority will be concluded.

A Data and Safety Monitoring Board will oversee the trial. An interim analysis will be performed after the first 50% of the target sample have completed the 90-day study period. The Data and Safety Monitoring Board can make a binding recommendation to terminate the study if the results of the interim analysis indicate very high likelihood for positive effect or futility.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Escherichia Coli Bacteremia Klebsiella Bacteraemia Enterobacter Bacteraemia Serratia Bacteraemia Citrobacter Bacteraemia Proteus Bacteraemia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Computer generated block randomization into permuted blocks of 4, 6 and 8

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

IV Group

Eligible patients randomized to complete their antimicrobial therapy course through intravenous (IV) administration.

Group Type ACTIVE_COMPARATOR

IV antimicrobial therapy

Intervention Type OTHER

No step down from intravenous to oral antimicrobial therapy to complete the intended course of treatment.

Oral Group

Eligible patients randomized to step down to oral antimicrobial therapy for the remainder of their treatment course.

Group Type EXPERIMENTAL

Step down to oral antimicrobial therapy

Intervention Type OTHER

Step down from intravenous to oral antimicrobial therapy to complete the intended course of treatment.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Step down to oral antimicrobial therapy

Step down from intravenous to oral antimicrobial therapy to complete the intended course of treatment.

Intervention Type OTHER

IV antimicrobial therapy

No step down from intravenous to oral antimicrobial therapy to complete the intended course of treatment.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age ≥18 years.
* Mono-microbial blood stream infection.
* Isolation of E. coli, Klebsiella species, Enterobacter species, Serratia species, Citrobacter species, or Proteus species from ≥1 blood culture(s).
* Adequate source control within ≤5 days of staring in-vitro active intravenous antimicrobial therapy.
* Afebrile (Tmax \<38 degrees Celsius) for ≥48 hours.
* Hemodynamically stable for ≥48 hours (SBP ≥100 mmHg, no vasopressors).
* Microbiologically active intravenous therapy for 3-5 days.
* Bloodstreams isolate in-vitro susceptibility to amoxicillin, amoxicillin-clavulanate, fluoroquinolones, oral cephalosporins and/or trimethoprim-sulfamethoxazole.
* Ability to take oral medication directly or through a feeding tube.

Exclusion Criteria

* Allergy to all in-vitro active antibiotics which are available in oral formulations.
* Pregnancy.
* Infective endocarditis.
* Central nervous system infection.
* Terminal illness with expected survival \<14 days.
* Neutropenia (absolute neutrophil count \<1.0x10\^9/L).
* Hematopoietic or solid organ transplantation within the preceding 90 days.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No